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| INTRODUC TI ON
Type 2 diabetes mellitus (T2DM) is a progressive disease usually requiring the addition of multiple antihyperglycaemic agents to achieve and maintain adequate glycaemic control over time. The typical pattern of diabetes treatment begins with lifestyle adjustment and monotherapy with metformin, progresses to dual therapy with oral agents and/or injectable treatments, and most patients with T2DM will eventually require therapy with insulin. In the United Kingdom Prospective Diabetes Study, 53% of newly diagnosed T2DM patients treated with sulfonylurea (SU) monotherapy required the addition of insulin over 6 years, albeit at a time when availability of non-insulin treatments was limited. Although an effective and safe treatment at any stage of diabetes, transition to insulin for many patients is considered a marker of "end-stage disease" or of a failure of diabetes care. Barriers to insulin use include patients' fear of injections or side effects of insulin (most commonly hypoglycaemia) or of stigma and discrimination.
Clinicians' lack of time, knowledge or experience in providing appropriate patient education and training in insulin use poses additional obstacles.
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The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a randomized, placebo-controlled cardiovascular outcomes trial comparing sitagliptin with placebo when added to usual care, provides an opportunity to examine international patterns of pharmacological diabetes treatment, thresholds for the addition of insulin and the degree to which sitagliptin therapy, compared with placebo, delays the onset of insulin use in a large, international cohort.
| RE S E ARCH DE S I G N AND ME THODS

| Study design and participants
The design, protocol and primary results of TECOS (NCT00790205)
have been published previously. 
| Statistical analysis
The intention-to-treat population was used for all analyses. Baseline AEs collected within TECOS included those that met SAE reporting criteria, and those that resulted in cessation of study medication;
however, study end-points and expected diabetes complications (as listed on the TECOS clinical event list 7 ) were not included in the AE analyses. Other non-serious AEs were not collected. AEs were analysed in the all-patients-as-treated population, comprising all randomized patients who received at least one dose of study medication.
AEs were analysed as binary variables. Counts and proportions of patients with events were reported, along with Miettinen-Nurminen 95% CIs for the risk difference between sitagliptin and placebo.
| RE SULTS
Baseline characteristics by treatment group have been published, 8 with characteristics by medication class shown in Table 1 Table S1 . Further results listed here are only for those medication classes used at baseline in >5% of the population, which included metformin, SU, metformin/SU combination, insulin and insulin/metformin combination.
Metformin and SU monotherapy users had shorter median (IQR)
duration of diabetes (6 [3, 10] and 8 [5, 13] years, respectively), users of metformin/SU combination therapy had an intermediate median diabetes duration (11 [6, 16] years), while insulin (17 [11, 24] ) and insulin/metformin (16 [11, 22] ) users had the longest duration (Table 1 and Figure 1 ). Asian participants were numerically less likely to be using insulin. Renal function parameters were consistent with clinical guidelines for medication use (highest eGFR for metformin, lower in insulin and SU users) as were proportions of patients with heart failure (lowest in metformin-containing regimens).
Calculated over the duration of follow-up, estimated overall mean HbA1c (95% CI) was 0.28% (−0.30 to −0.26) lower in the sitagliptin group compared with the placebo group and was similarly reduced in all groups by baseline diabetes medication class (Table S2) In those patients not using insulin at baseline, insulin was initiated in 4.7% of metformin monotherapy users over a median follow-up of 3.0 years, 11.0% of SU monotherapy users over a median follow-up of 3.1 years and 17.2% of metformin/SU combination therapy users over a median 3.2 years' follow-up. Overall, the mean (SD) HbA1c value at the time of insulin initiation was 8.5% (1.5%) and was lower for those on metformin monotherapy (8 (Figure 3 ).
Event rates for incident severe hypoglycaemia were lowest in patients using metformin monotherapy at baseline, somewhat higher in those using SU or metformin/SU combination therapy and highest in those using insulin alone or in combination ( Table 2 ). The likelihood of severe hypoglycaemia was not significantly different for sitagliptin compared with placebo, either overall or according to baseline glucose-lowering medication use. Similar patterns were observed when baseline non-insulin users were censored after the initiation of SU or insulin (data not shown). There were no differences between treatment groups in the frequency of AEs or SAEs (Table   S3 ) according to baseline medication use.
| CON CLUS IONS
The TECOS study was conducted in conjunction with usual community-based diabetes care according to local treatment guidelines.
Our analysis shows that TECOS participants, a cohort with reasonably well-controlled diabetes at baseline, broadly followed expected patterns of diabetes medication use. The majority of patients were using one or two oral agents at baseline, and the choice of baseline medication paralleled median diabetes duration, ranging from the shortest duration in metformin monotherapy users (6 years) to the longest (17 years) in those receiving insulin monotherapy.
Intensification of therapy also showed progression from mono-to dual-oral agent therapy and then to insulin alone or in combination.
Severe hypoglycaemia was more common in patients using regimens containing SU or insulin, but rates were not impacted by randomization to sitagliptin or placebo.
This paper examines the real-world progression of glucose-lowering diabetes therapy (per the trial protocol) 7 "as deemed necessary by the usual care physician … to achieve an appropriate, individualized glycaemic goal in line with national guidelines," rather than protocol-imposed targets. TECOS provides a structured opportunity to make these observations globally on the treatment standards in effect at the time the trial was conducted. Insulin was added in 8.8%
of TECOS participants during a median 3.0 years of follow-up, with the median HbA1c of 8.5% at the time of initiation higher than the 6.5%-7% target suggested in contemporaneous international guidelines. Within TECOS, treatment with sitagliptin was associated with improved glycaemic control and a delayed use of insulin in patients receiving metformin monotherapy or combination therapy with metformin and SU. The finding that sitagliptin had no impact on time to insulin when added to SU monotherapy may be related to patient selection for SU therapy, resulting in a cohort with minimal capacity for additional beta-cell stimulation by a DPP-4 inhibitor. It is also possible that a delay does exist, supported by the apparent separation of the time to insulin curves at 2 years, but that the sample size in this subgroup was too small to detect a difference between treatment groups statistically. More rapid progression to insulin in patients using SU was also shown in ADOPT (A Diabetes Outcome Progression Trial) 18 and may be an intrinsic property of SU therapy due to chronic insulin stimulation.
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In clinical practice, intensification of diabetes regimens may confer increased risk of hypoglycaemia. In TECOS, patients randomized to sitagliptin achieved lower HbA1c values throughout follow-up without experiencing an increased risk for severe hypoglycaemia.
The same was true regardless of baseline therapy, although it should be noted that the TECOS protocol encouraged down-titration of concomitant medications if severe hypoglycaemia developed, rather than study drug discontinuation. This is in contrast to earlier studies suggesting that rates of hypoglycaemia were higher when sitagliptin was added to medications with intrinsic increased risk for hypoglycaemia (eg, SU or insulin), but not when added to medications without significant increased hypoglycaemia risk (eg, metformin).
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Interpretation of these findings is limited by several features of 
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